IN BRIEF: Destiny Pharma's Morgan to step down from board in March
IN BRIEF: Destiny Pharma's Morgan to step down from board in March
Read moreMon, 07th Sep 2020 08:57
IN BRIEF: Destiny Pharma's Morgan to step down from board in March
Read moreTRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru
Read more(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.
Read moreIN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project
Read more(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Monday that its China regional partner and investor, China Medical System Holdings (CMS), is establishing a new programme with 'XF-73' targeting the prevention and treatment of superficial skin infections caused by bacteria.
Read moreEARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black
Read moreUK earnings, trading statements calendar - next 7 days
Read moreTRADING UPDATES: Brickability buys Leadcraft; Aquis has record July
Read more(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced additional, "strong" data from its recent phase 2b clinical trial on Monday.
Read moreTRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays
Read more(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced a cooperative research and development agreement with the US Department of Veterans' Affairs on Tuesday, to support studies focusing on identifying new attributes for 'NTCD-M3' - a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections in the gut.
Read moreTRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing
Read moreTRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent
Read moreTRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows
Read more(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive progress with its lead clinical programme, 'NTCD-M3', on Wednesday.
Read more